💎 Fed’s first rate cut since 2020 set to trigger market. Find undervalued gems with Fair ValueSee Undervalued Stocks

Pfizer beats by USD0.04, beats on revenue

Published 01/28/2014, 07:20 AM
Pfizer reports Q4 EPS of USD0.56, beats on revenue
NDX
-
US500
-
DJI
-

Investing.com - U.S. pharmaceutical giant Pfizer reported better-than-expected fourth quarter earnings and revenue figures ahead of Tuesday’s opening bell.

Pfizer said adjusted earnings per share came in at USD0.56 during the fourth quarter, above expectations for earnings of USD0.52 per share. The company’s fourth quarter revenue totaled USD13.56 billion, surpassing forecasts for revenue of USD13.37 billion.

Pfizer said it expected adjusted full-year earnings to come in at a range between USD2.20 to USD2.30 per share, compared to expectations for earnings of USD2.28 per share.

Ian Read, Chairman and Chief Executive Officer, stated, “We enter 2014 with confidence in the competitive positioning of our commercial businesses, the prospects for our recently launched products and the strength of our research pipeline.”

Following the release of the report, Pfizer shares rose 2% in pre-market trade.

Meanwhile, the outlook for U.S. equity markets was mixed. The Dow Jones Industrial Average futures indicated a gain of 0.6% at the open, S&P 500 futures pointed to a rise of 0.45%, while Nasdaq 100 futures dipped 0.35% ahead of the open.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.